anti-PD1 agent therapy - 1 year for endometrial neoplasms

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 9 Sep 2026: Trial started, NCT07867002
  2. 9 Oct 2026: Trial registered, NCT07867002

The trials

NCT07867002: Assessing Survival Outcomes With Checkpoint Inhibition ExteNded vs Discontinued in Endometrial Cancer

State
Under way
Phase
Phase 3
People
140 planned
Started
9 Sep 2026
Primary completion
Oct 2032
Arms
anti-PD1 maintenance therapy -1 year
Results
None posted
  1. 9 Sep 2026: Trial started
  2. 9 Oct 2026: Trial registered

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.